IR@PKUHSC  > 北京大学药学院  > 药剂学系
学科主题药学
Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections
Wang, Taotao1; Zhu, Huifang2; Sun, Jinyao1; Cheng, Xiaoliang1,3; Xie, Jiao1; Dong, Haiyan1; Chen, Limei4; Wang, Xue5; Xing, Jianfeng6; Dong, Yalin1
关键词Voriconazole Efficacy Safety Hepatotoxicity Cyp2c19 Trough Plasma Concentrations
刊名INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
2014-11-01
DOI10.1016/j.ijantimicag.2014.07.013
44期:5页:436-442
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Infectious Diseases ; Microbiology ; Pharmacology & Pharmacy
研究领域[WOS]Infectious Diseases ; Microbiology ; Pharmacology & Pharmacy
关键词[WOS]INTRAVENOUS VORICONAZOLE ; ANTIFUNGAL AGENT ; PHARMACOKINETICS ; MULTICENTER ; IDENTIFICATION ; GENOTYPE ; TRIAZOLE
英文摘要

The aim of this study was to determine an optimum voriconazole target concentration, to study the influence of CYP2C19 gene status on metabolism of voriconazole and to identify a dose-adjustment strategy for voriconazole according to CYP2C19 polymorphism in patients with invasive fungal infections. A total of 328 voriconazole trough plasma concentrations (C-min) were collected and monitored from 144 patients. Information on efficacy and safety was obtained. Voriconazole therapy was effective in 81.9% of patients (118/144), and 12.5% (18/144) exhibited signs of hepatotoxicity. The relationships between voriconazole C-min and clinical response and hepatotoxicity were explored using logistic regression, and a target clinical C-min range of 1.5-4 mg/L was identified. Values of voriconazole C-min and the ratio of C-min to concentration of voriconazole-N-oxide ( Cmin/CN) of poor metabolisers (PMs) were significantly higher than extensive metabolisers and intermediate metabolisers. Model-based simulations showed that PM patients could be safely and effectively treated with 200 mg twice daily orally or intravenously, and non-PM patients with 300 mg twice daily orally or 200 mg twice daily intravenously. This study highlighted that voriconazole C-min and C-min/C-N are strongly influenced by CYP2C19 polymorphism, and gene-adjusted dosing is important to achieve therapeutic levels that maximise therapeutic response and minimise hepatotoxicity. (C) 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

语种英语
WOS记录号WOS:000344938800010
Citation statistics
Cited Times:25[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52529
Collection北京大学药学院_药剂学系
作者单位1.Tengzhou Cent Peoples Hosp, Dept Pharm, Tengzhou 277500, Peoples R China
2.Xi An Jiao Tong Univ, Affiliated Hosp 1, Coll Med, Dept Pharm, Xian 710061, Peoples R China
3.Peking Univ, Hlth Sci Ctr, Sch Pharmaceut Sci, Dept Pharmaceut, Beijing 100871, Peoples R China
4.Xi An Jiao Tong Univ, Affiliated Hosp 1, Coll Med, Dept Hematol, Xian 710061, Peoples R China
5.Xi An Jiao Tong Univ, Affiliated Hosp 1, Coll Med, Cent Intens Care Unit, Xian 710061, Peoples R China
6.Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Pharm, Xian 710061, Peoples R China
Recommended Citation
GB/T 7714
Wang, Taotao,Zhu, Huifang,Sun, Jinyao,et al. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections[J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS,2014,44(5):436-442.
APA Wang, Taotao.,Zhu, Huifang.,Sun, Jinyao.,Cheng, Xiaoliang.,Xie, Jiao.,...&Dong, Yalin.(2014).Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections.INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS,44(5),436-442.
MLA Wang, Taotao,et al."Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections".INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS 44.5(2014):436-442.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Wang, Taotao]'s Articles
[Zhu, Huifang]'s Articles
[Sun, Jinyao]'s Articles
百度学术
百度学术Similar articles in
[Wang, Taotao]'s Articles
[Zhu, Huifang]'s Articles
[Sun, Jinyao]'s Articles
必应学术
必应学术Similar articles in
[Wang, Taotao]'s Articles
[Zhu, Huifang]'s Articles
[Sun, Jinyao]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.